Gyre Therapeutics (NASDAQ:GYRE) Stock Rating Upgraded by Zacks Research

Gyre Therapeutics (NASDAQ:GYRE) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a report issued on Monday,Zacks.com reports.

Several other research firms have also commented on GYRE. Weiss Ratings lowered shares of Gyre Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 11th. Wall Street Zen cut Gyre Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $17.00.

Gyre Therapeutics Price Performance

NASDAQ:GYRE opened at $7.01 on Monday. The firm has a market capitalization of $781.54 million, a price-to-earnings ratio of -77.88 and a beta of 1.89. The company’s 50-day moving average is $6.52 and its two-hundred day moving average is $7.25. Gyre Therapeutics has a 1-year low of $5.44 and a 1-year high of $9.42.

Insider Activity at Gyre Therapeutics

In other news, CEO Ying Luo sold 10,136 shares of Gyre Therapeutics stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $8.04, for a total value of $81,493.44. Following the completion of the sale, the chief executive officer directly owned 2,565,226 shares of the company’s stock, valued at approximately $20,624,417.04. The trade was a 0.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, COO Weiguo Ye sold 12,820 shares of the business’s stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $6.15, for a total value of $78,843.00. Following the completion of the sale, the chief operating officer owned 700,000 shares in the company, valued at $4,305,000. This represents a 1.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 32,535 shares of company stock valued at $219,580 in the last quarter. 9.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Gyre Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Millennium Management LLC purchased a new stake in Gyre Therapeutics during the third quarter worth about $267,000. Goldman Sachs Group Inc. boosted its stake in shares of Gyre Therapeutics by 72.5% in the fourth quarter. Goldman Sachs Group Inc. now owns 31,108 shares of the company’s stock valued at $220,000 after purchasing an additional 13,074 shares during the period. Alliancebernstein L.P. grew its holdings in shares of Gyre Therapeutics by 9.5% in the third quarter. Alliancebernstein L.P. now owns 21,830 shares of the company’s stock valued at $163,000 after purchasing an additional 1,900 shares in the last quarter. Barclays PLC increased its stake in Gyre Therapeutics by 38.3% during the 4th quarter. Barclays PLC now owns 18,531 shares of the company’s stock worth $131,000 after buying an additional 5,135 shares during the period. Finally, Lazard Asset Management LLC purchased a new stake in Gyre Therapeutics during the 3rd quarter worth approximately $111,000. 23.99% of the stock is currently owned by hedge funds and other institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.